The firm's quarterly earnings of 13 cents per share came in line with analyst estimates, while revenue came in at $3.66 billion, missing expectations. The company's customer base rose 17% ...
In mid-July, the stock for the cancer drug developer MEI Pharma skyrocketed. It wasn’t because the small company, first listed on the Nasdaq in 2003, had discovered a blockbuster cancer cure. Rather, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback